AIM ImmunoTech Inc.
AIM
Rank in Stocks
#29998
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida,... AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Share Price
$0.157
Last synced: 2026-11-09
Market Cap
$6.26M
Change (1 day)
1.29%
Change (1 year)
-89.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AIM ImmunoTech Inc. (AIM)
Category
Healthcare
Operating Margin for AIM ImmunoTech Inc. (AIM)
Operating Margin as of November 2026 TTM: -11,637.89%
According to AIM ImmunoTech Inc.'s latest financial reports, its current operating margin (TTM) is -11,637.89%. At the end of 2025 the company had an operating margin of -11,961.36%.
Operating Margin history for AIM ImmunoTech Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -11,637.89% | -2.70% |
| 2025 | -11,961.36% | 2.84% |
| 2024 | -11,630.59% | -26.39% |
| 2023 | -15,800.00% | 11.82% |
| 2022 | -14,129.65% | 1.26% |
| 2021 | -13,954.07% | 50.11% |
| 2020 | -9,295.71% | 4.59% |
| 2019 | -8,887.86% | 183.74% |
| 2018 | -3,132.43% | 19.91% |
| 2017 | -2,612.36% | -82.59% |
| 2016 | -15,004.35% | 19.85% |
| 2015 | -12,518.80% | 29.13% |
| 2014 | -9,694.92% | -15.29% |
| 2013 | -11,444.67% | 19.85% |
| 2012 | -9,549.30% | 7.55% |
| 2011 | -8,878.88% | -26.85% |
| 2010 | -12,138.52% | 1.58% |
| 2009 | -11,949.55% | 147.18% |
| 2008 | -4,834.34% | 172.85% |
| 2007 | -1,771.77% | -11.57% |
| 2006 | -2,003.64% | 118.86% |
| 2005 | -915.51% | 3.33% |
| 2004 | -886.00% | -19.73% |
| 2003 | -1,103.81% | -43.14% |
| 2002 | -1,941.35% | -13.98% |
| 2001 | -2,256.92% | 96.67% |
| 2000 | -1,147.59% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about AIM ImmunoTech Inc.'s operating margin
What is AIM ImmunoTech Inc.'s operating margin?
AIM ImmunoTech Inc.'s operating margin is -11,637.89%, as of Nov 2026.
What was AIM ImmunoTech Inc.'s operating margin in 2025?
In 2025, AIM ImmunoTech Inc.'s operating margin was -11,961.36%, compared with -11,630.59% in 2024.
How has AIM ImmunoTech Inc.'s operating margin changed since 2020?
From 2020 to 2025, AIM ImmunoTech Inc.'s operating margin was highest in 2020 (-9,295.71%) and lowest in 2023 (-15,800.00%).
How does AIM ImmunoTech Inc.'s operating margin compare with similar companies?
AIM ImmunoTech Inc.'s operating margin (-11,637.89%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.